Green-lipped mussel extract (Perna canaliculus) and glucosamine sulphate in patients with knee osteoarthritis: therapeutic efficacy and effects on gastrointestinal microbiota profiles
- First Online:
To investigate how changes in the gastrointestinal tract (GIT) microbiota profile may influence nutraceutical efficacy in osteoarthritis (OA) and allow the formulation of a hypothesis that explains in part the inconsistent and contentious findings from OA clinical studies with green-lipped mussel (GLM) and glucosamine.
A non-blinded randomised clinical trial was conducted with 38 subjects diagnosed with knee OA. Each participant received either 3,000 mg/day of a whole GLM extract or 3,000 mg/day of glucosamine sulphate (GS), p.o. for 12 weeks. Faecal microbial analyses were carried out after collecting stools at T0 and T12 weeks. Additional pharmacometric measures were obtained from changes in arthritic scores in the Western Ontario McMaster Universities Arthritis Index (WOMAC) and the Lequesne algofunctional indices and the Gastrointestinal Symptom Rating Scale (GSRS). An intention-to-treat analysis was employed and participant data collected at T0, T6 and T12 weeks.
There were no statistically significant changes in bacterial growth patterns determined by the Wilcoxon test. In both groups there was a trend towards a decrease in Clostridium and Staphylococcus species and increase in Lactobacillus, Streptococcus and Eubacterium species. In the GLM group Bifidobacterium tended to increase and Enterococcus and yeast species to decrease. The GS-treated group demonstrated a trend towards a decrease in Bacteroides and an increase in yeasts and Coliforms species, most notably Escherichia coli. We further confirm significant improvement (p < 0.05) in all OA outcome measures from T0 to T12 weeks for both the GLM and GS groups. The GSRS scores indicated that GIT function significantly improved over the 12 weeks duration with GLM and GS supplementation.
Both GLM and GS reduced OA symptoms and non-significantly altered the gut microbiota profile from baseline. Changes in the microbiota profiles occurred in both treatment groups; the most notable being a reduction in the Clostridia sp. This study suggests that nutritional supplements such as GLM and GS may regulate some of the metabolic and immunological activities of the GIT microbiota. The decrease in Clostridia, a potent modulator of colonic Th17 and CD4+ regulatory T cells, was consistent with a decrease in inflammation; improved GSRS scores and OA symptoms for these OA participants. The GIT microbiota may be important factor in the first-pass metabolism of these nutraceuticals.
KeywordsGastrointestinal tract Microbiota Green-lipped mussel Perna canaliculus Glucosamine Osteoarthritis Clostridia sp.
- Chong V, Wang C (2008) Higher prevalence of gastrointestinal symptoms among patients with rheumatic disorders. Singap Med J 49(5):419–424Google Scholar
- Rutjes A, Nüesch E, Reichenbach S, Jüni P (2008) S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 4:CD007321Google Scholar
- Tana C, Umesaki Y, Imaoka A et al (2010) Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 22(5):512–519, e114–e115Google Scholar
- Thrupp L (1980) Susceptibility testing of antibiotics in liquid media. In: Lorian V (ed) Antibiotics in laboratory medicine, chap 4. Williams & Wilkins pub, Baltimore, pp 73–113Google Scholar
- Towheed T, Maxwell L, Anastassiades TP et al (2005) Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2:CD002946Google Scholar
- Vitetta L, Briskey D, Hayes E et al (2012) A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics. Inflammopharmacology (Epub ahead of print)Google Scholar
- Willis A (2007) Anaerobic culture methods, in anaerobic microbiology: a practical approach. IRL Press at Oxford University Press, OxfordGoogle Scholar